NEW genderless connectors® for innovative sterile connections - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

NEW genderless connectors® for innovative sterile connections


New genderless AseptiQuik® G Connectors from Colder Products Company make single-use sterile connections faster, easier and safer than ever before—even in non-sterile conditions.

The genderless design eliminates separate male and female components, allowing any G series connectors to mate together.  This universal “G” mating simplifies systems integration and increases process flexibility for transferring valuable media.

The unique design of AseptiQuik G connectors minimizes the risk of operator error, reduces complexity, labor and inventory requirements. The new G series is available in a full range of interchangeable 1/4” to 3/4” flow solutions, in both gamma and high-temperature versions. Terminations include 1/4” hose barb, 1/2” hose barb, 3/4” hose barb and 3/4” sanitary.

The AseptiQuik family of connectors—in a full range of 1/8” to 1” flow configurations—provides unequalled ease of use and robust construction for reliable, repeatable performance without burdensome assembly aids, clamps or tube welding. AseptiQuik connectors are ideal for single-use bag and tubing assemblies, bioreactors, mixers, sampling and filling applications.  For applications where reliability and sterility are a must, Connect with Colder.

See how easy connections are with AseptiQuik® G —click here for video.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here